Introduction
Pseudomonas aeruginosa is a Gram-negative bacterium that is responsible for a significant level of hospital-acquired infections, particularly in burn victims, immunocompromised and cystic fibrosis patients (Kerr & Snelling, 2009; Ratjen & Dö ring, 2003) . There is an urgent need for the development of new antibiotics that tackle this and related drug-resistant Gram-negative bacteria (Payne et al., 2007; Shlaes, 2003) . One way forward involves a structure-based approach, in particular by exploiting accurate chemical information provided by the crystallographic analyses of carefully considered molecular targets (Hunter, 2009) . A potential target for antibiotic drug discovery is -ketoacyl-(acyl-carrier-protein) synthase II (FabF), which is one of the essential elongation condensing enzymes of fatty-acid biosynthesis (Wang et al., 2006) , a highly conserved metabolic pathway among key microbial pathogens. During fatty-acid elongation the acyl-carrier protein (ACP) substrate transfers a fatty acid to the S atom of the catalytic cysteine of FabF. The malonyl-ACP substrate then interacts with the acyl-enzyme intermediate and forms a -ketoacyl-ACP product. FabF requires a catalytic triad (Zhang et al., 2006) , which in the P. aeruginosa enzyme (PaFabF) comprises Cys164, His304 and His341.
FabF has been validated in Gram-positive bacteria as the target for the natural products platensimycin ( Fig. 1 ; Wang et al., 2006) and fasamycin A and B (Feng et al., 2012) . Platensimycin, although inactive against wild-type Gram-negative bacteria, is active against efflux-negative Escherichia coli (Wang et al., 2006) . Similarly, the fasamycins are active against membrane-permeabilized Escherichia coli but not the unaltered strain (Feng et al., 2012) . These observations suggest that the absence of activity against Gram-negative bacteria of these FabF inhibitors is owing to their inability to access their target. This issue might potentially be overcome by developing chemical matter based on different scaffolds which are more easily taken up by Gram-negative bacteria and that might avoid efflux mechanisms.
We now report the preparation and use of an efficient recombinant protein-production system and purification and crystallization protocols for the enzyme from P. aeruginosa (PaFabF; UniProt code G3XDA2) and for an active-site C164Q mutant. The mutant is believed to mimic the substratebound state of FabF (Wang et al., 2006) . Crystal structures of both the apoenzyme and mutant are reported. These provide accurate templates to support structure-based approaches to search out molecules with the right properties to tackle Gram-negative bacteria. In PaFabF we noted a buried, highly ordered potassium-binding site that might represent a conserved feature of FabF that is important for fold stability. Comparison with the previously known structure of the enzyme from E. coli (EcFabF; PDB entry 2gfw; Wang et al., 2006) revealed the highly conserved character of the overall structure, the catalytic centre and the monovalent cationbinding site. Attempts to co-crystallize PaFabF and the mutant with commercially available small-molecule fragments of platensimycin resulted in the structure of the complex with compound 1 [3-(benzoylamino)-2-hydroxybenzoic acid; Fig. 1] . Surprisingly, this compound did not bind in the active site but rather occupies a site between two symmetry-related molecules.
Methods

Recombinant protein production and purification
PaFabF was obtained following a similar strategy to one described previously (Moynie et al., 2013) . The gene was cloned into the pNIC28-Bsa4 vector (GenBank ID EF198106; Stols et al., 2002) encoding a tobacco etch virus (TEV) cleavage site and an N-terminal hexahistidine tag. The new plasmid was heat-shock transformed into BL21(DE3)pLysS competent E. coli cells (Novagen), which were cultured in 1 l autoinduction medium (MgSO 4 /NPS-5052) supplemented with kanamycin (50 mg ml À1 ) and chloramphenicol (25 mg ml À1 ) for 48 h at 293 K. The cells were harvested by centrifugation (30 min, 3500g, 277 K), resuspended in lysis buffer [25 mM Tris-HCl pH 8.5, 500 mM NaCl, 20 mM imidazole, one tablet of protease-inhibitor EDTA-free cocktail (Roche), 0.1 mg DNase (Sigma)] and lysed by mechanical disruption using a French pressure-cell press at 110 MPa. Centrifugation of the sample (30 min, 277 K, 40 000g) was followed by passage through 0.2 mm filters to remove debris. The protein was then purified using an Ni 2+ Sepharose High Performance HisTrap HP 5 ml column (GE Healthcare) with an increasing imidazole gradient to 500 mM for elution. The fractions containing PaFabF were pooled and His-tagged TEV protease was added to remove the affinity tag. The mixture was dialyzed with buffer (25 mM Tris-HCl pH 7.5, 150 mM NaCl) overnight at 277 K and the cleaved protein was purified by passage through an Ni 2+ -charged HisTrap column. Sizeexclusion chromatography was then performed on a Superdex 200 HiLoad 26/60 prep-grade column (GE Healthcare) with equilibration buffer (25 mM Tris-HCl pH 7.5, 150 mM NaCl). The column had previously been calibrated with molecularmass standards (thyroglobulin, 670 kDa; -globulin, 158 kDa; serum albumin, 67 kDa; ovalbumin; 44 kDa, myoglobin, 17 kDa; vitamin B 12 , 1 kDa). A high level of purity was confirmed by SDS-PAGE (Mini-PROTEAN TGX Stain-Free Precast Gel; Bio-Rad) and the recovery of PaFabF was determined using a NanoVue spectrophotometer (GE Healthcare).
Protein production and purification of the PaFabF
C164Q mutant
In vitro site-directed mutagenesis using the Agilent QuikChange kit was carried out using the PaFabF gene carrying the pNic28-Bsa4 vector to mutate Cys164 to Gln164. The PCR product generated using the forward primer 5 0 -GCCCT-CACCACCGCCCAGACCACCGGTACCCAC-3 0 and the research communications Figure 1 Chemical structures of (a) platensimycin and (b) 3-(benzoylamino)-2-hydroxybenzoic acid (compound 1).
reverse primer 5
0 -GTGGGTACCGGTGGTCTGGGCGGT-GGTGAGGGC-3 0 was treated with the DpnI restriction enzyme (Biolabs) to digest the methylated template plasmid. The restriction sites are shown in bold. The PaFabF-C164Q encoding plasmid was amplified by transforming E. coli XL1-Blue supercompetent cells (Novagen). Plasmid DNA was extracted (QIAprep Spin Miniprep Kit, Qiagen) and verified by DNA sequencing (DNA Sequencing Unit, University of Dundee). Overexpression and protein purification were performed as described for wild-type PaFabF but using phosphate buffer [50 mM Na 2 HPO 4 pH 7.8, 300 mM NaCl, 10%(v/v) glycerol, 0.5 mM DTT]. This was necessary to avoid precipitation of the mutant protein.
Crystallization and X-ray data collection
Crystallization screens were performed with a Phoenix liquid-handling system (Art Robbins Instruments, Rigaku) using sitting-drop vapour-diffusion conditions in 96-well plates and commercial screens from Hampton Research and Qiagen. Optimization led to planar crystals (250 Â 100 Â 10 mm) using a reservoir consisting of 0.2 M MgCl 2 , 0.1 M Tris-HCl pH 7.0, 10%(w/v) PEG 8000 and a protein solution consisting of 20 mg ml À1 PaFabF in 25 mM Tris-HCl pH 7.5, 150 mM NaCl. Plate-shaped crystals (100 Â 100 Â 5 mm) of PaFabF-C164Q were obtained at 20 mg ml À1 [in 50 mM Na 2 HPO 4 pH 7.8, 150 mM NaCl, 10%(v/v) glycerol, 0.5 mM DTT] with a reservoir consisting of 0.2 M NH 4 HCO 2 , 25%(w/v) PEG 3350. For both the wild-type and the mutant PaFabF crystals, 1 ml protein solution and 1 ml reservoir solution were equilibrated against 60 ml reservoir solution in sitting drops at 293 K in MRC crystallization plates (catalogue No. MD11-00-10, Molecular Dimensions). For the structure of the complex with compound 1, 1 ml wild-type protein (20 mg ml À1 in 25 mM Tris-HCl pH 7.5), 0.5 ml of a 10 mM solution of compound 1 in DMSO and 0.5 ml reservoir solution were equilibrated against 60 ml reservoir solution [0.2 M MgCl 2 , 0.1 M Tris-HCl pH 7.0, 10%(w/v) PEG 8000]. Attempts to co-crystallize compound 1 with the mutant protein were unsuccessful. Compound 1 was ordered from Vitas-M Laboratory Ltd (code STK685369) and its identity and purity (>99%) were verified by LC-MS (data not shown).
Crystals were transferred to a cryoprotectant based on the reservoir adjusted to contain 25%(v/v) glycerol prior to research communications is the intensity of the ith measurement of reflection hkl and hI(hkl)i is the mean value of I i (hkl) for all i measurements. ‡ R work = P hkl jF obs j À jF calc j = P hkl jF obs j, where F obs is the observed structure-factor amplitude and F calc is the structure-factor amplitude calculated from the model. R free is calculated with a subset of data that were excluded from refinement calculations (5%) using the same method as for R merge .
flash-cooling in liquid nitrogen. X-ray diffraction data for the apo and mutant structures were collected from single crystals with a MicroMax-007 HF X-ray generator equipped with a Saturn 944 HG CCD detector (Rigaku). The data for the complex structure were collected from a single crystal on a Bruker AXS Microstar-H generator with a MAR Scanner 345 mm image-plate detector. In each case crystals were maintained at 100 K and the X-ray wavelength was 1.5418 Å (Cu K). Data were processed using XDS (Kabsch, 2010) and SCALA (Evans, 2006) .
Structure solution and refinement
The structures were solved by molecular replacement using Phaser (McCoy, 2007) . The apo PaFabF form was first determined using the homologous monomer (chain A) of EcFabF (PDB entry 2gfw), with 67% sequence identity, as a search model. The structure of PaFabF was refined and subsequently used as the starting model for analysis of the other two structures. Refinements involved least-squares calculations performed in REFMAC5 (Murshudov et al., 2011) interspersed with inspection of electron-density and difference density maps and model manipulation using Coot (Emsley & Cowtan, 2004) . During the course of the refinements, water molecules and side-chain conformers were included. The model geometry was assessed using MolProbity (Chen et al., 2010) and the PDB validation tools. The properties of the dimer interface were investigated with PISA (Krissinel & Henrick, 2007) . The crystallographic data and refinement statistics are listed in Table 1 . The figures were generated with PyMOL v.1.5.0.4 (Schrö dinger).
Results and discussion
Structure of apo PaFabF
An efficient recombinant PaFabF production system has been established that produces in excess of 10 mg of pure enzyme per litre of bacterial culture. The apoenzyme crystallized in space group P2 1 with two molecules in the asymmetric unit and the structure was determined to 1.73 Å resolution (Table 1, Fig. 2 ). Size-exclusion chromatography, which was used during purification, consistently indicated a single species with a molecular mass of approximately 55 kDa. This value lies between the theoretical values for a monomer (43 kDa) and a dimer (86 kDa). Analysis of the crystal structure using PISA (Krissinel & Henrick, 2007) suggested that the dimer present in the asymmetric unit is stable in solution. The accessible surface area of a subunit is estimated to be 15 460 Å 2 and the area occluded by dimer formation is about 2840 Å 2 . The dimer interface is therefore formed using approximately 20% of the total subunit surface and the solvation free-energy gain is estimated to be À221 kJ mol À1 , suggesting a stable entity. The presence of a PaFabF dimer is also consistent with previous work on the E. coli enzyme (Edwards et al., 1997) .
The PaFabF subunit consists of 14 -sheets, 12 -helices and four 3 10 -helices (Fig. 2) . The -strands can be divided into two sets of five. 4, 5 and 6 are parallel and 1 and 7 are antiparallel and form the first unit, whereas the parallel 9, 10 and 13 and the antiparallel 8 and 14 form the second unit. These two sections enclose the two helices 6 and 12. The two sets of helices 3, 5 and 9, 10 are packed against the domain. Accordingly, the monomer exhibits a globular research communications five-layered structure, ----. The overall fold and architecture of the active site is highly conserved in orthologous structures, for example the E. coli enzyme (Huang et al., 1998) .
The PaFabF dimer displays approximate dimensions of 60 Â 50 Â 40 Å (Fig. 2) . A large dimer interface area, with significant hydrophobic properties, maintains the quaternary structure. Hydrophobic interactions are mainly observed through the self-association of residues in 7, 5 and 4, the two 3 10 -helices and 5. The -sheets of each subunit run antiparallel to each other, which thus forms a continuous sheet through the interface of the two monomers. The loop bordered by 4 and 5, containing 4 and two 3 10 -helices, is in close interaction with the related loop in the other monomer. Helix 5 is also in contact with the C-terminal end of 8 and 13 of the second monomer.
The active site and the C164Q mutant
There is one active site in each subunit. This is a narrow cleft in which the three catalytic residues are placed (Fig. 3) . To further investigate the active site, a PaFabF-C164Q mutant was generated that mimics the acyl-enzyme intermediate, thereby forming a competent state to bind the inhibitor platensimycin (Wang et al., 2006) . The PaFabF-C164Q mutant crystallized in a different space group (C222 1 ; Table 1 ) compared with the wild-type structure and the structure was determined to 2.40 Å resolution. A dimer constitutes the asymmetric unit and the structure is essentially identical to that of the wild type, with an r.m.s.d. of 0.24 Å for the overlay of all C atoms. The binding-site residues are also well aligned, although we note that Phe400 is rotated away from the catalytic centre owing to an extension in the length of residue 164, where glutamine replaces cysteine (Fig. 3) . This results in a binding pocket that is slightly more open and Phe400 can then participate in hydrophobic interactions with a symmetryrelated molecule. Such a change may contribute to the different crystal form that is observed for the mutant.
A potassium ion binding site
A striking and unusual observation is the identification of a buried cation approximately 8 Å from the catalytic Cys164 in all three structures. Care was taken in the assignment of this ion based on correlation of difference density (F o À F c ) levels with the number of electrons (Fyfe et al., 2009; Rimsa et al., 2011) . The exclusion of all eight S atoms in PaFabF produced positive peaks in the difference density map with an average height of 18.6. At the position of the ion an average peak height of 21.9 was obtained. This, together with the coordination geometry, is consistent with the assignment of a potassium ion. In all three structures the satisfactory refinement of potassium ions with full occupancy was noted and resulted in the same octahedral environment for the ion. The octahedral coordination involves O atoms from five different residues (Fig. 4) . Asn302 coordinates in a bidentate mode to the potassium ion using the side-chain and main-chain O atoms. Other coordinating O atoms are from the side chains of Glu350 and Ser395 and the main chains of Ala303 and Asn396. The distances between the ion and the coordinating atoms are within the predicted 2.59-2.97 Å distances noted for potassium ion binding (Harding, 2002) . The side-chain atoms and the potassium ion show similar B factors of approximately 13 Å 2 . No potassium was added to the buffers that were used for purification or to the crystallization reagents; therefore, we conclude that this group I ion was acquired during production in the heterologous expression system.
The fact that the ion is completely buried and has a coordination sphere encompassing residues in different elements of secondary structure suggests a contributing role whereby The active site. (a) A view into the narrow active-site cleft of the wild-type enzyme. The van der Waals radii are depicted as a grey semi-transparent surface. Residues are shown as sticks coloured by atomic position (purple, C; red, O; blue, N; yellow, S). Red spheres are waters. Three key catalytic residues are labelled. (b) Superposition of the wild-type and C164Q mutant active sites. The same colour scheme for atoms is used as in (a) except that the C atoms of the mutant are in orange. As a result of the C164Q mutation, Phe400 rotates out of the binding pocket.
this polypeptide folds into a catalytically competent entity. If this were true it might be expected that FabF orthologues could show a similar feature and, indeed, comparison with other FabF structures shows that this might be the case. The two asparagine residues, the alanine and glutamate are highly conserved in FabF sequences and structures. The serine, whilst well maintained, is conservatively substituted by cysteine or threonine. The 1.9 Å resolution structure of EcFabF (PDB entry 3i8p; Singh et al., 2009 ) has a buried water assigned at this site, with similar geometry to that we observe except that Cys395 replaces the serine. The B-factor value of about 6 Å 2 for this water molecule is one third of that of the coordinating groups, which are amongst the most ordered in EcFabF, and the difference density map reveals a positive peak of 6 at the water position. We judge it likely that this is actually a cation and not a water and is likely to be potassium. Other FabF structures at lower resolution all have highly ordered water molecules assigned at this position with at least fivefold coordination and a geometry that would be consistent with cation binding. This is exemplified by the structures of the enzymes from Vibrio cholerae (PDB entry 4jrm; Center for Structural Genomics of Infectious Diseases, unpublished work) and Bacillus subtilis (PDB entry 4ls8; Trajtenberg et al., 2014) . Here also, the only amino-acid difference at the potassium ion-binding site involves the replacement of the serine with Cys397 in the V. cholerae enzyme. A polyketide synthase fold relative (PDB entry 1tqy; Keatinge-Clay et al., 2004) displays a similar buried cation-binding site where a magnesium ion is assigned. Ser395 and Asn396 of PaFabF correspond to Thr400 and Val401 in this related structure. In the latter case it is the main chain that interacts with the cation, so the nature of the side chain is less important. This buried ion has escaped comment but we judge it to be supportive of our conclusion that such a site might be particularly relevant to the stability of this enzyme fold.
Complex with compound 1
Compounds representing fragments of platensimycin were sought to investigate the molecular-recognition properties of the substrate-binding site. To this end, the ChemSpider database (http://www.chemspider.com) was used to identify compounds containing an aromatic substructure with a similar substitution pattern as in platensimycin. After visual inspection, 20 compounds were purchased for further evaluation. In the absence of an established binding or inhibition assay, we attempted to use crystallographic methods to investigate binding. Soaking of pre-formed apoenzyme crystals in soluresearch communications tions of potential ligands led to degradation of the crystalline order or to no electron density for the ligands. The compounds were also subjected to co-crystallization trials with the wild type and the PaFabF-C164Q mutant and gave only a single success. A new crystal form (PaFabF-compound 1) in space group P4 3 2 1 2 resulted and the structure was determined to 1.67 Å resolution (Table 1) . A single subunit is present in the asymmetric unit and a crystallographic twofold axis of symmetry generates the dimer observed in all other FabF structures. Unexpectedly, the potential ligand did not occupy the active site, but difference density was clearly visible on the surface of the enzyme near two symmetry-related molecules (Fig. 5) . The binding might be considered as that of an ion pair, since Mg 2+ , coordinated by a carboxylic O atom of compound 1, in addition to numerous solvent-mediated links, helps to stabilize the complex and this crystal form (Fig. 5) . In addition, hydrophobic interactions of compound 1 contribute to the well ordered mode of binding. Adjacent to the divalent cationbinding site, the hydroxybenzoic acid moiety makes van der Waals interactions with Phe83, Val86 and Val151 on one side of the ring and with Arg128 and Arg129 of a symmetry mate on the other. Nearby, but not in direct interaction, is another symmetry-related subunit. The benzoylamino segment is stacked between Tyr62 and Arg87 from one subunit. As the binding site is located at a crystallographic interface it appears that it is a crystallographic artefact, and binding of the compound in aqueous solution cannot be concluded from this crystal structure.
Compound 1 and platensimycin share a common substructure, but we note that we are aware of no evidence which indicates that the former has any inhibitory activity against FabF. Both compounds contain a 3-amino-2-hydroxybenzoic acid moiety, albeit compound 1 lacks a hydroxyl group in the para position to the carboxylate. The structure of the EcFabF-C164Q mutant in complex with platensimycin has been determined (Wang et al., 2006) . In this complex, the 2-hydroxy group is not involved in direct interactions and the 4-hydroxy group, which is lacking in compound 1, forms a hydrogen bond to a water molecule. The carboxylate group of the compound interacts with the catalytic histidine residues and the amide group interacts with a nearby threonine (Wang et al., 2006) . These residues are all strictly conserved. However, access to the depths of the active site of the PaFabF apoenzyme is restricted by the conformations of Phe230 and Phe400. The side chain of the latter residue is forced to adopt a different conformation when the cysteine is changed to a glutamine. The compound 1-Mg 2+ ion pair selectively binds into and perhaps contributes to the formation of a stable binding site on the surface of the enzyme distant from the active site, from which it is likely to be occluded by steric hindrance.
Conclusions
We have developed an efficient recombinant protein-production system and purification protocols for a potentially valuable antibacterial drug target, PaFabF. Three structures in distinct crystal forms are reported. Our study provides reagents, templates and high-resolution structural information that can inform target-based drug-discovery projects for urgently needed antibacterial substances with a new mode of action.
